Gordon Rees Scully Mansukhani partners Peter Siachos, Travis Richins, and Clair Wischusen, together with associate Bates Holman, recently secured a significant victory for Epic Pharma in the long-running multidistrict litigation In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending before the Honorable Cynthia M. Rufe in the United States District Court for the Eastern District of Pennsylvania.
In a detailed memorandum opinion, the Court granted Epic’s motions to dismiss three separate antitrust complaints brought by CVS Pharmacy, Molina Healthcare (an administers government health plans), and Health Care Service Corporation (Blue Cross Blue Shield in five states) against Epic Pharma. The ruling removes Epic entirely from those actions and represents an important development in the most closely watched antitrust pharma MDL. The nearly decade-old MDL involves dozens of pharmaceutical manufacturers and wholesale purchasers and centers on allegations that generic drug manufacturers engaged in industrywide conspiracies to fix prices for numerous medications. Plaintiffs sought to link Epic to an alleged conspiracy involving the generic drug ursodiol.
The Court rejected those allegations. In its opinion, the Court concluded that the complaints failed to plausibly allege sufficient agreement or conspiratorial conduct involving Epic. Instead, the pleadings relied largely on generalized allegations about industry conditions, market behavior, and parallel price increases, without identifying any meetings, communications, or coordinated conduct tying Epic to an unlawful agreement. The Court held that such allegations are insufficient under the governing antitrust pleading standards and dismissed the claims against Epic in their entirety.
The ruling also underscores a strategic litigation decision made early in the case by the GRSM defense team. Rather than simply joining the consolidated motions to dismiss filed by other defendants, Epic pursued complaint-specific motions tailored to the allegations asserted against it by each plaintiff. That strategy proved decisive. While claims against other defendants remain pending in the MDL, Epic was dismissed entirely from three separate cases at the pleading stage, an outcome that significantly narrows the claims asserted against the company and eliminates substantial discovery exposure in those actions. The ruling demonstrates how a surgical, client-focused motion strategy can produce meaningful early victories even in complex, multi-defendant MDL proceedings.
The decision represents a major milestone in the defense of Epic within the sprawling MDL proceedings. It reflects both the Court’s careful application of modern antitrust pleading standards and the effectiveness of Epic’s litigation strategy in challenging circumstantial and conclusory conspiratorial allegations early and often. The GRSM team continues to represent Epic Pharma in the remaining MDL proceedings and will pursue additional dispositive motions as the litigation progresses.